Bayer AG / Schiff Nutrition International, Inc.

Vitamins, minerals & dietary supplements (consumer health)

$30.0B Global VMS market ~$30B at deal time

Disease Overview

This is a consumer-health/nutraceutical transaction rather than a therapeutic disease indication. Schiff sold over-the-counter dietary supplements addressing self-managed wellness needs — cardiovascular (omega-3), joint health (glucosamine), and immune support — categories where consumers self-direct purchase decisions, distinct from prescription pharma economics.

Competitive Landscape

The 2012 global VMS market was approximately $30B, highly fragmented with no competitor holding more than ~5% share — making it attractive consolidation territory for consumer-health acquirers. Schiff was the #2 US dietary supplements company with three flagship brands: MegaRed (krill omega-3, cardiovascular), Move Free (glucosamine/chondroitin, joint health), and Airborne (immune support). Competitive landscape included Pfizer's Centrum/Caltrate franchise (later sold to GSK then Haleon), NBTY (Nature's Bounty/Sundown), and private-label retailer brands. Bayer's October 30, 2012 agreement at $34/share ($1.2B) was challenged by Reckitt Benckiser's superior $42/share ($1.4B, 23.5% premium) bid on November 21, 2012. Bayer declined to match and walked away, allowing Reckitt to close the acquisition and use Schiff as its entry into the VMS category alongside Mucinex, Nurofen, and Durex. The deal terminated for Bayer is tagged as 'borderline pharma' in this database — relevant as a Big Pharma consumer-health pivot signal. Bayer subsequently grew its consumer health business through other transactions, notably the 2014 acquisition of Merck & Co.'s OTC business. (Sources: https://www.prnewswire.com/news-releases/bayer-to-acquire-schiff-nutrition-international-for-us-12-billion-176367771.html ; https://cen.acs.org/articles/90/i48/Reckitt-Outbids-Bayer-Schiff-Nutrition.html)